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Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by the destruction of bone
and cartilage. Although its etiology is unknown, the hydroxyl radical has been suggested to be involved in the
pathogenesis of RA. Recently, molecular hydrogen (H2) was demonstrated to be a selective scavenger for the
hydroxyl radical. Also, the method to prepare water containing extremely high concentration of H2 has been
developed. We hypothesized that H2 in the water could complement conventional therapy by reducing the
oxidative stress in RA.
Methods: Twenty patients with rheumatoid arthritis (RA) drank 530 ml of water containing 4 to 5 ppm molecular
hydrogen (high H2 water) every day for 4 weeks. After a 4-week wash-out period, the patients drank the high H2
water for another 4 weeks. Urinary 8-hydroxydeoxyguanine (8-OHdG) and disease activity (DAS28, using C-reactive
protein [CRP] levels) was estimated at the end of each 4-week period.
Results: Drinking high H2 water seems to raise the concentration of H2 more than the H2 saturated (1.6 ppm)
water in vivo. Urinary 8-OHdG was significantly reduced by 14.3% (p < 0.01) on average. DAS28 also decreased from
3.83 to 3.02 (p < 0.01) during the same period. After the wash-out period, both the urinary 8-OHdG and the mean
DAS28 decreased, compared to the end of the drinking period. During the second drinking period, the mean
DAS28 was reduced from 2.83 to 2.26 (p < 0.01). Urinary 8-OHdG was not further reduced but remained below the
baseline value. All the 5 patients with early RA (duration < 12 months) who did not show antibodies against cyclic
citrullinated peptides (ACPAs) achieved remission, and 4 of them became symptom-free at the end of the study.
Conclusions: The results suggest that the hydroxyl radical scavenger H2 effectively reduces oxidative stress in
patients with this condition. The symptoms of RA were significantly improved with high H2 water.
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Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease that affects approximately 1% of the population. It is
characterized by irreversible joint disorder accompanied
by destruction of bone and cartilage. In addition, the
chronic inflammation associated with RA often damages
the skin, subcutaneous tissue, and the lungs and cardio-
vascular system, including the pleura, pericardium,
thereby diminishing the quality of life and survival time
[1]. Although the etiology is unknown, RA is certainly
associated with autoimmune disorders, and its pathogen-
esis has been well investigated [2]. Auto-reactive T cells
that infiltrate the synovial tissue promote the immune re-
sponse and lead to overproduction of pro-inflammatory
cytokines such as TNF-α and IL6. Thus, early therapy was
based on aggressive biologic modification of the disease by
controlling the synovial T cells and/or suppressing the
levels of the cytokines implicated in the disease.
Apart from the present immunogenic targets, reactive
oxygen species (ROS) are of considerable interest. ROS is
spontaneously produced as by-product during electron
transfer in oxidative phosphorylation [3,4]. They are also
actively produced by NADPH oxidase, which play import-
ant roles in the immune system [5,6]. ROS include super-
oxide, peroxide, hydroxyl radicals and reactive nitrogen
species. They oxidize various cellular and extracellular
components, including nucleotides, DNA, proteins, poly-
saccharides, and lipids, by the unpaired free radicals. The
numerous products that appear to be generated by ROS
have been identified in clinical samples including periph-
eral blood and fluid from the joints in patients with RA
[7-9]. Among them, 8-hydroxyguanine (8-OHdG), which
is produced by the oxidation of guanine bases in DNA
and also in the nucleotide pools, is important [10-12].
8-OHdG is a standard biomarker for oxidative stress.
Numerous studies have reported that 8-OHdG accumu-
lates in diseases related to oxidative stress, such as can-
cer, diabetes mellitus, Alzheimer’s disease, hypertension,
chronic renal disease, cardiovascular disease, metabolic
syndrome and autoimmune disease [13-18]. Elevated
levels of 8-OHdG have been reported in RA [16].
Hydroxyl radical is the most toxic ROS due to the det-
rimental effects of its rapid and indiscriminate reactivity.
Is has been shown that molecular hydrogen (H2) elimi-
nates the hydroxyl radical in cultured cells and living
organisms [19,20]. H2 does not have any influence on
the other ROS, including superoxide, peroxide, and ni-
tric oxide; these ROS play important roles in the defence
system or in signal transduction [19]. In humans, the
safety of H2 has been tested, especially in the field of
deep diving; in contrast to general drugs, which usually
have some harmful effects, no cytotoxicity was found
even at high concentrations of H2 [21,22]. H2 is an inert
gas present within the human body and is not classifiedas a medicine, but it has been shown to have therapeutic
potential for acute or chronic inflammatory diseases
related to ROS [20,23]. H2 dissolved in water has already
been used in the clinical treatment of type II diabetes
mellitus [24] and metabolic syndrome [25].
At present, there is no evidence that H2 provides benefits
for patients with RA. We might expect H2 to complement
or provide a substitute for conventional therapy by redu-
cing oxidative stress in RA, especially where existing drugs
are insufficient in efficacy or are discontinued due to harm-
ful side effects or due to financial considerations. H2 may
also be useful for patients with early RA, in whom anti-
bodies against cyclic citrullinated peptides (ACPAs) are
below standard values. ACPAs are positive in about two-
thirds of patients with RA and are associated with rapid
joint destruction and a poor prognosis [26,27]. Patients at
high risk are targeted for early aggressive immunosuppres-
sive therapy. We therefore expected that the introduction
of H2 into ACPA-negative patients with recent-onset RA
may help rule out transient or non-aggressive RA.
In the present study, we tested the effects of drinking
water containing a high concentration of hydrogen (high
H2 water) as an anti-oxidant supplement against the hy-
droxyl radical, among patients with RA.
Methods
Patients
Twenty-two patients who fulfilled the 1987 and 2010
American College of Rheumatology criteria for RA were
enrolled. All patients gave their informed consent to en-
roll in the study, and this study was approved by the
Haradoi Hospital Ethics Committee. Two of the patients
left the study during the first period. One patient did not
continue drinking the water daily during winter, and the
other declined to provide a blood sample every 4 weeks.
The remaining 20 patients completed the study and the
data are summarized in Table 1.
Five patients with early RA (disease duration<12 months)
who were diagnosed at our hospital were included in the
study; four of them had not received any medication before
the study. Patients with disease duration > 12 months
had been administered disease-modifying anti-rheum-
atic drugs (DMARDs) and/or biological drugs. Twelve
patients had been treated with methotrexate (MTX),
two with abatacept (500 mg/4 w), and 1 patient with
both drugs. One patient did not receive DMARDs, be-
cause she had swelling in only 1 joint for more than
2 years and occasional swelling in another joint. Two
patients had discontinued therapy with MTX or bio-
logical drugs because of harmful side effects. None of
the 20 patients had been treated with steroid hor-
mones. In addition to MTX and abatacept, patients
continued any other regular medication that they were
on during the study.
Table 1 Clinical effects of high H2 water and patient characteristics at baseline, and 4, 8, and 12 weeks
Patients Disease
duration
Urinary 8-OHdG (ng/mg Cr) DAS28 ACPA (U/ml) Medications





Patient number Sex Age Y M Y M Y M
1 F 67 3 2 10.1 10.0 7.7 6.0 3.28 2.45 2.40 1.94 300 204 254 226 6 2 0 500 1 2 good
2 F 69 5 0 18.0 16.2 12.0 11.5 2.90 2.95 2.53 2.62 <0.6 <0.6 <0.6 <0.6 4 2 1 non-response
3 F 76 11 0 11.0 8.1 7.8 7.8 4.61 3.71 3.28 3.01 52.4 47.2 58.0 56.6 6 3 0 good
4 F 51 2 1 11.4 11.3 9.1 9.4 3.00 2.79 2.86 2.30 <0.6 <0.6 <0.6 <0.6 6 1 6 moderate
5 F 41 2 0 10.9 9.9 11.3 10.0 4.55 3.43 3.06 3.13 6.9 6.2 9.2 14.5 none good
6 F 42 2 2 15.3 12.6 11.6 10.8 4.63 4.03 2.44 2.57 <0.6 <0.6 <0.6 <0.6 6 1 4 good
7 F 86 5 0 10.0 6.5 7.1 7.1 4.67 3.79 3.78 3.00 0.8 <0.6 <0.6 <0.6 none good
8 F 40 10 0 nd nd 3.9 4.9 2.88 1.25 1.50 0.99 13.5 14.5 15.4 16.8 6 2 2 good
9 F 41 2 1 8.7 7.7 7.3 9.0 5.38 4.35 4.37 4.22 34.3 36.4 57.6 65.7 8 1 6 moderate
10 M 55 2 3 9.3 8.3 9.7 11.5 4.62 3.44 3.28 3.06 532 258 299 223 6 1 8 good
11 F 56 2 0 12.0 8.2 10.8 10.9 5.47 5.22 5.06 4.16 <0.6 <0.6 <0.6 <0.6 500 0 8 good
12 M 40 2 1 5.2 4.9 4.9 6.4 1.95 1.96 1.52 1.59 <0.6 <0.6 <0.6 <0.6 6 1 4 non-response
13 F 64 13 0 nd 8.1 11.2 9.0 2.72 2.14 2.32 2.21 490 299 266 256 4 7 0 non-response
14 F 58 2 0 10.7 8.4 8.5 10.5 3.21 3.03 2.93 3.04 <0.6 <0.6 <0.6 <0.6 6 1 2 non-response
15 F 74 3 0 6.5 6.8 5.7 5.3 2.91 2.52 2.30 1.30 <0.6 <0.6 <0.6 <0.6 none good
16 F 69 0 8 7.6 6.5 8.6 5.4 4.07 2.78 2.54 0.99 2 3.7 <0.6 1.9 none good
17 M 42 0 9 7.9 5.7 6.6 7.2 3.25 2.03 2.27 1.11 <0.6 <0.6 <0.6 <0.6 6 6 good
18 F 49 0 5 10.6 8.5 7.2 9.3 4.91 3.46 2.83 1.17 <0.6 <0.6 <0.6 <0.6 none good
19 F 57 0 10 9.5 9.4 9.2 10.7 3.38 2.87 2.50 1.82 <0.6 <0.6 <0.6 <0.6 none good
20 F 41 0 8 5.2 5.0 4.4 3.8 4.20 2.29 2.91 0.99 <0.6 <0.6 <0.6 <0.6 none good
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ease activity score in 28 joints, using C-reactive protein
levels (DAS28). Remission (DAS28< 2.3) and the decrease
in the DAS28 was evaluated as good, moderate, or a non-
response according to the European League against
Rheumatism (EULAR) response criteria. The DAS28 was
evaluated at baseline, after 4 weeks of drinking high H2
water, at 8 weeks after the wash-out period, and at
12 weeks after another 4 weeks of drinking the water.
Study design
The study began in August in 2011, lasted 12 weeks
and included a wash-out period. The patients drank
water containing a high concentration of hydrogen
(4 to 5 ppm H2 water) daily for 4 weeks, followed
by a wash-out period of 4 weeks. They then drank the
high H2 water again for another 4 weeks. They consumed
530 ml of the water within 1 h every day during the 4-
week drinking period. The patients themselves dissolved
the H2 in 530 ml of water each day just before drinking.
They were asked to drink it as soon as possible, within a
maximum of 1 h of opening the bottle. During the wash-
out period, the patients did not consume any water
without H2.
Preparation of the high H2 water
Hydrogen gas was produced in an acrylic resin tube in a
PET bottle to provide a carbonated drink containing
530 ml water. The amount of 530 ml fills the entire PET
bottle with no space for air, which allows the highest
concentration of H2 to be present. The material for pro-
ducing molecular hydrogen was prepared by mixing 75%
weight of metal aluminum grains and 25% weight of cal-
cium hydroxide; 0.5 g of the material was enclosed and
heat-sealed within a non-woven fabric. After insertion
into an acrylic resin tube and the addition of 0.5 ml of
water, a cap with a check valve was tightly closed. This
was to prevent the drinking water from entering the
tube while allowing the gas to permeate it. In about
5 min at room temperature, the material starts a reac-
tion in the wet fabric. The reaction is as follows:
2Alþ Ca OHð Þ2 þ 2H2O! Ca AlO2ð Þ2 þ 3 H2
The H2 gas produced is emitted into the water in the
PET bottle through the check valve attached to
the acrylic resin tube. During the procedures therefore,
the chemical compound as well as the water for the reac-
tion does not come into contact with the drinking water.
During the reaction, the hydrogen gas lowers the surface
of the water in the standing bottle, which is gradually
hardened by the increasing pressure within it. After the
reaction is terminated, the hydrogen gas is dissolved by
shaking the bottle by decantation for about 30 s. Theconcentration of hydrogen gas in the water was measured
according to a previously reported method [28] and veri-
fied by the apparatus, model DHD1-1 (DKK-TOA Corpor-
ation, Tokyo, Japan). The H2 saturated (approximately
1.6 ppm) water was produced using AQUELA BLUE in-
strument electrolysis (MiZ Company and ecomo Inter-
national Co., Ltd) [29]. H2 exhaled in the breath of three
independent volunteers was measured using BAS200
(Mitleben R&D Associates).
Measurements of urinary 8-hydroxydeoxyguanine (8-OHdG)
and serum ACPA
The defined marker for oxidative stress, urinary 8-OHdG,
which reflects 8-hydroxyguanine in DNA, was measured
according to the procedure based on the ELISA
method [30]. The assay was performed at Mitsubishi
Chemical Medience Inc. (Tokyo, Japan), using the test kit
New 8-OHdG Check ELISA (manufactured by the Japan
Institute for the Control of Aging Inc., Shizuoka, Japan).
ACPAs in the serum samples were assayed at SRL Inc.
(Tokyo, Japan) using the ELISA kit (MESACUP-2 test
CCP; MBL Inc., Tokyo, Japan).
Statistical analysis
One-way repeated measure analysis of variance (ANOVA)
was used to identify significant differences. In repeated
measures ANOVA, the sphericity assumption was always
violated. In order to account for this violation, the degrees
of freedom were adjusted using the Greenhouse-Geisser
correction. Bonferroni’s multiple comparison was used as
the post-hoc test. All data analyses were performed using
SPSS Statistics 20.
Results
As shown in Figure 1a, the concentration of H2 in the
drinking water exceeded 5 ppm (5.40 ± 0.12 mg/L) and
remained above 4 ppm (4.22±0.15 mg/L) 1 h after the cap
was opened. Accordingly, the amount of hydrogen in the
bottle was between 2.1 mg to 2.7 mg. As shown in
Figure 1b, the concentration of H2 exhaled in the breath
before drinking the H2 saturated water and the high H2
water were 15.7± 2.5 ppm and 14.0± 4.0 ppm, respectively.
These concentrations in the baseline are close to the data
previously reported [31]. In 5 minutes the peak concentra-
tion was 102.7±34.0 ppm and 278.3± 37.5 ppm, respect-
ively. It gradually decreased in 60 minutes and returned to
near baseline level, 14.0± 1.0 ppm and 15.3±2.1 ppm,
respectively. Drinking high H2 water raises the concen-
tration of H2 more than the conventional H2 saturated
water in vivo.
During the drinking period, patients usually passed
urine 1 or 2 times more than usual, as they drank the
extra water. No other adverse effects were observed.
Figure 1 a Concentration of H2 in the water at each time point.
The concentrations were measured immediately after preparation,
and at 1 and 2 h after preparation. The error bars represent the
mean and standard deviation (SD) for 5 independent measurements.
b Concentration of H2 in the water with 1.6 ppm H2 (circle) or with
5 ppm H2 (square) at each time point. The concentrations were
measured before drinking and every 5 minutes after drinking. The
error bars represent the mean and standard deviation (SD) for 3
independent measurements.
Figure 2 Urinary 8-OHdG in 18 patients measured at baseline
and at 4, 8 and 12 weeks. Error bars represent the mean and
standard deviation (SD) for measurements in 18 patients.
Ishibashi et al. Medical Gas Research 2012, 2:27 Page 5 of 8
http://www.medicalgasresearch.com/content/2/1/27Urinary 8-OHdG was analyzed in 18 patients (Table 1).
During the first 4 weeks, 8-OHdG decreased in 17 of
these patients after drinking the high H2 water. As
shown in Figure 2, the mean decrease in 8-OHdG
among the 18 patients was 14.3% (9.99 to 8.56 ng/mg
Cr, p < 0.01). Drinking the high H2 water for 4 weeks
affected the urinary 8-OHdG for 4 weeks after the
wash-out period, with urinary 8-OHdG remaining
below the baseline level at the end of the break (mean,
8.31 ng/mg Cr). The patients did not drink extra water
during this period and the frequency of urination did not
increase. At 12 weeks, urinary 8-OHdG had decreased by
15.1% (9.99 to 8.48 ng/mg Cr, p < 0.01). Nine of the eight-
een patients had decreased urinary 8-OHdG in both drink-
ing periods. There was no increase in urinary 8-OHdG in
either drinking period.
The DAS28 results are shown in Table 1. The scores
decreased in 18 of the 20 patients during the first
drinking period, with a decrease more than 0.6 points in
12 of the patients, indicating a significant improvement
in the symptoms of RA. Moderate improvement
(0.6 <DAS28 ≤ 1.2) was observed in 6 patients and good
improvement (DAS28 >1.2) in 6 other patients. After the
wash-out period, the DAS28 remained better than that
at the baseline in all 20 patients. In 14 of the 20 patients,
the scores remained below the level immediately after
the first drinking period. At the end of the study, 16
patients showed significant improvement in the DAS28.
Two of these had a moderate response and fourteen had
a good response. Nine patients achieved remission
(DAS28 < 2.3), except for one patient who had been in
remission at the baseline assessment. Although all 20
patients had decreased disease activity at the end of the
study, 4 patients did not experience improvement in
symptoms (DAS28≤ 0.6). On average, the score decreased
from 3.83 to 3.02 (p < 0.01) in the first drinking period and
from 2.83 to 2.26 (p< 0.01) in the second drinking period
(Figure 3). During the wash-out period, the DAS28Figure 3 DAS28 scores at baseline, and 4, 8 and 12 weeks. Error
bars represent the mean and standard deviation (SD) for
measurements in 20 patients.
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2.83.
Five patients (numbers 16 to 20 in Table 1) had been
classified as having early RA (duration < 12 months) and
were ACPA-negative. Four of them had not taken any
medications for RA before the study. The patients’
symptoms improved by more than 0.6 points in the first
drinking period. At the end of the study, their DAS28
scores were all below 2.3, indicating that remission was
achieved. Four of the patients did not report any swollen
or painful joints and were symptom-free.
Seven of the 20 patients were ACPA-positive (above
4.9 U/ml) at each time point (Table 1). The ACPA levels
were below 100 U/ml in 4 patients at baseline and did
not decrease during the study; the levels showed slight
increase in three patients. The disease activity, however,
improved in the 4 patients. Three of them showed a
good response and one of them a moderate response.
On the other hand, in three patients with ACPA above
300 U/ml, there was a mean decrease from 441 U/ml to
235 U/ml. The response was diverse among the patients,
with a good response observed in 2 patients and no re-
sponse in another. Although the direct effect of high H2
on ACPA is unclear at present, 5 of the 7 ACPA-positive
patients showed a good response to high H2 water, as
assessed by improvement in the DAS28.
Discussion
Many studies have demonstrated that ROS play some
noteworthy roles in the pathogenesis of RA, and conse-
quently, they have become therapeutic targets in this con-
dition. The ROS scavenger superoxide dismutase (SOD)
was expected to have clinical efficacy, and initially, bovine
SOD was injected into the joints of patients with RA [32].
However, in relation to the exogenous SOD protein,
results from clinical trials have not been reproduced.
Simulators of SOD, which have been shown to have con-
siderable anti-inflammatory effects in animal models of
arthritis, are still being investigated [33,34]. Edaravone,
which is approved for the treatment of acute ischemic
stroke, is another ROS scavenger [35]. A clinical report
describes treatment of a patient with RA and ischemic
stroke with edaravone, and raises the possibility of further
clinical trials [36], but the results do not establish whether
ROS scavengers are efficient in reducing the disease activ-
ity in patients with RA. Direct evidence is also lacking
about whether ROS prime the autoimmune response or
reduce chronic inflammation in RA.
Molecular hydrogen stands out as an antioxidant due
to its selectivity for the hydroxyl radical and its perme-
ability [19]. Its physical properties allow it to diffuse
through the cellular membranes and rapidly leave the
body. Due to these properties of H2 we expected reduc-
tion in ROS in RA patients with a better efficacy. In ourstudy, patients who drank the high H2 water had marked
reduction in disease activity, and a significant decrease
in urinary 8-OHdG.
It has been demonstrated that molecular hydrogen
ameliorates inflammation by down-regulating TNF-α
[20,37]. It is known that ROS including hydroxyl radicals
function as second messengers for the production of
TNF-α [38,39]. There is a possibility that the anti-
inflammatory properties by H2 may be through inhib-
ition of the TNF-α pathway. It has been reported that
hydrogen-rich saline prevented neointima formation by
suppressing the NF-kB and TNF-α cascade which is
involved in the redox-sensitive mechanisms in immune
system [40]. The reduction of 8-OHdG and the disease
activity in RA patients presented here could be the
results of downregulation of TNF-α pathway through
scavenging hydroxyl radicals which occur upstream of
the inflammatory cascade.
It should be noted that the influence of H2 on the dis-
ease activities and oxidative stress was sustained even
during the wash-out period. These continuous anti-
inflammatory effects of H2 are observed with both the
ACPA-negative and the ACPA-positive patients who
were treated with immunosuppressive medications. The
marker for oxidative stress, 8-hydroxyguanine is highly
mutagenic because it pairs with adenine as well as cyto-
sine. These properties cause partial phenotypic suppres-
sion during transcription as well as transversion
mutations during DNA replication [41]. It is likely that
the error proteins, produced as a result of the altered
genetic information, therefore, are identified as foreign
molecules and play a role as neo-epitopes [42,43]. They
would then continue to activate the immune system.
The sustained effects of H2 during the wash out period
may reflect the decrease of such neo-epitope. On the
other hand, there was no significant decrease of DAS28
during the washout period. It may indicate that the
pathogenesis of RA did not disappear completely at the
end of the first drinking period. It is necessary to investi-
gate the transition of pro-inflammatory cytokines includ-
ing TNF-α, both during the drinking period and wash
out period for further studies.
The prognosis of RA has improved during this decade,
and a so-called paradigm shift has been achieved using
early aggressive therapy to biologically modify the dis-
ease [44,45]. Remission is not difficult to achieve; how-
ever, it is difficult to determine the role of drugs in
remission [2]. It is difficult to determine at which stage
patients will be able to discontinue medication without
recurrence of inflammation, and sustained medication is
often necessary. Most of these problems are attributed
to the intense immunosuppressive procedures, and the
epitopes involved are still unknown. Patients with RA
are classified according to their prognosis, as having
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modifying biologic therapy, or as having transient RA,
which may show spontaneous remission. It is difficult to
distinguish transient from progressive RA in the early
stages [46].
Although ACPAs have been useful for diagnosing RA,
they are less sensitive (48%) in early RA [26]. In the
present study, the 5 patients with early onset and ACPA-
negative RA all achieved remission after drinking the high
H2 water; possibly, some of them had transient RA.
In total 47.4% of patients (9/19) achieved the remis-
sion, except for one patient who had been in remission
at the baseline assessment. Although the efficacy of H2
presented here is not inferior to those in recently
reported studies on tocilizumab [47], adalimumab plus
MTX [48] or MTX monotherapy [49] , the study here is
non-controlled, on a smaller scale and also, the patient
background and the period of medication varied. Estima-
tion of the efficacy of high H2 water in RA patients
should be done carefully in a further placebo-controlled
study. The high H2 water was produced in a bottle by
using a novel high-pressure method. Since molecular
hydrogen is a very small molecule and is easily lost even
through the wall of PET bottles with the passage of time,
the patients had to prepare it themselves every day. Also,
H2 is an inert gas having no taste or smell. It was diffi-
cult to set up placebo controls using another inert gas
and a similar preparation. However, it is important to in-
clude placebo controls in future studies.
Conclusion
We suggest that high H2 water may be useful to comple-
ment conventional RA therapy by reducing oxidative
stress, especially in early stage and ACPA-negative RA, to
assist diagnosis and treatment decisions. Further study is
required to confirm this theory. However, high H2 water is
freely available, and its benefits could also be demon-
strated spontaneously by observing the disease rates in
people who regularly drink it.
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